Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1
Spontaneous immune responses to the cancer testis antigen NY-ESO-1 are frequently found in cancer patients bearing antigen-expressing tumors. In HLA-A2-expressing patients, naturally elicited NY-ESO-1-specific, tumor-reactive cytotoxic T lymphocytes (CTLs) are mostly directed against an immunodomina...
Gespeichert in:
| Veröffentlicht in: | Journal of immunotherapy (1997) 2005-05, Vol.28 (3), p.252-257 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 257 |
|---|---|
| container_issue | 3 |
| container_start_page | 252 |
| container_title | Journal of immunotherapy (1997) |
| container_volume | 28 |
| creator | LE GAL, Frédérique-Anne AYYOUB, Maha DUTOIT, Valérie WIDMER, Valérie JÄGER, Elke CEROTTINI, Jean-Charles DIETRICH, Pierre-Yves VALMORI, Danila |
| description | Spontaneous immune responses to the cancer testis antigen NY-ESO-1 are frequently found in cancer patients bearing antigen-expressing tumors. In HLA-A2-expressing patients, naturally elicited NY-ESO-1-specific, tumor-reactive cytotoxic T lymphocytes (CTLs) are mostly directed against an immunodominant epitope corresponding to peptide NY-ESO-1 157-165. NY-ESO-1-specific CTLs can also be induced by synthetic peptide vaccines, but they are heterogeneous in terms of functional avidity and tumor reactivity. The authors investigated the structural bases of this phenomenon by analyzing the TCR features of natural and vaccine-induced NY-ESO-1-specific CTLs. The results indicate that CTLs from the two groups exhibit highly structurally conserved but distinct TCR features, suggesting that the synthetic peptides used for vaccination may fail to faithfully mimic the naturally processed antigen. Together, the results of this study underline the strength of TCR molecular monitoring and will be instrumental for the development and monitoring of vaccines aimed at eliciting CTLs with high tumor reactivity. |
| doi_str_mv | 10.1097/01.cji.0000161398.34701.26 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67757875</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67757875</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-3d4c52287f2355c3f842ee33a4df5fc714fb46169bc9dd56f2575bbc3ec617d93</originalsourceid><addsrcrecordid>eNpFkV1vFCEUhonR2Fr9C4aY2BvDyscAM96Z7YcmjU3s9sIrwpyBSjPLjMA06Z_ob5ZtN9nDxTmB57wHeBH6xOiK0U5_pWwF92FFazDFRNeuRKPrJlev0DGTQpNGMvF6V_OGdFLqI_Qu53tKueINf4uOmGxFXfwYPZ2FXEKEgnNJC5Ql2RFv1r9xcrNLZQrJZRwijvb5aHzEE8CSUoh3-MGlvGT8YAFCdCTEYQE34PVZ-wVvCLhxrCp5nmKuGmXC5a_DZdlOieTZQfABsI0l3LmIf_0h5zfXhL1Hb7wds_uwzyfo9uJ8s_5Brq4vf66_XxGoTy1EDA1IzlvtuZAShG8b7pwQthm89KBZ4_tGMdX10A2DVJ5LLfsehAPF9NCJE3T6ojun6d_icjHbkHc3ttFNSzZKa6lbLSv47QWENOWcnDdzClubHg2jZueGocxUN8zBDfPshuGqNn_cT1n6rRsOrfvvr8DnPWAz2NEnGyHkA6e04JwK8R88OpWe</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67757875</pqid></control><display><type>article</type><title>Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>LE GAL, Frédérique-Anne ; AYYOUB, Maha ; DUTOIT, Valérie ; WIDMER, Valérie ; JÄGER, Elke ; CEROTTINI, Jean-Charles ; DIETRICH, Pierre-Yves ; VALMORI, Danila</creator><creatorcontrib>LE GAL, Frédérique-Anne ; AYYOUB, Maha ; DUTOIT, Valérie ; WIDMER, Valérie ; JÄGER, Elke ; CEROTTINI, Jean-Charles ; DIETRICH, Pierre-Yves ; VALMORI, Danila</creatorcontrib><description>Spontaneous immune responses to the cancer testis antigen NY-ESO-1 are frequently found in cancer patients bearing antigen-expressing tumors. In HLA-A2-expressing patients, naturally elicited NY-ESO-1-specific, tumor-reactive cytotoxic T lymphocytes (CTLs) are mostly directed against an immunodominant epitope corresponding to peptide NY-ESO-1 157-165. NY-ESO-1-specific CTLs can also be induced by synthetic peptide vaccines, but they are heterogeneous in terms of functional avidity and tumor reactivity. The authors investigated the structural bases of this phenomenon by analyzing the TCR features of natural and vaccine-induced NY-ESO-1-specific CTLs. The results indicate that CTLs from the two groups exhibit highly structurally conserved but distinct TCR features, suggesting that the synthetic peptides used for vaccination may fail to faithfully mimic the naturally processed antigen. Together, the results of this study underline the strength of TCR molecular monitoring and will be instrumental for the development and monitoring of vaccines aimed at eliciting CTLs with high tumor reactivity.</description><identifier>ISSN: 1524-9557</identifier><identifier>EISSN: 1537-4513</identifier><identifier>DOI: 10.1097/01.cji.0000161398.34701.26</identifier><identifier>PMID: 15838382</identifier><identifier>CODEN: JOIMF8</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Amino Acid Sequence ; Antigens, Neoplasm - immunology ; Antineoplastic agents ; Biological and medical sciences ; Cancer Vaccines - immunology ; Humans ; Immunotherapy ; Medical sciences ; Molecular Sequence Data ; Neoplasm Proteins - immunology ; Peptide Fragments - immunology ; Pharmacology. Drug treatments ; Receptors, Antigen, T-Cell - chemistry ; T-Lymphocytes, Cytotoxic - immunology ; Vaccines, Subunit - immunology</subject><ispartof>Journal of immunotherapy (1997), 2005-05, Vol.28 (3), p.252-257</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-3d4c52287f2355c3f842ee33a4df5fc714fb46169bc9dd56f2575bbc3ec617d93</citedby><cites>FETCH-LOGICAL-c347t-3d4c52287f2355c3f842ee33a4df5fc714fb46169bc9dd56f2575bbc3ec617d93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16732203$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15838382$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LE GAL, Frédérique-Anne</creatorcontrib><creatorcontrib>AYYOUB, Maha</creatorcontrib><creatorcontrib>DUTOIT, Valérie</creatorcontrib><creatorcontrib>WIDMER, Valérie</creatorcontrib><creatorcontrib>JÄGER, Elke</creatorcontrib><creatorcontrib>CEROTTINI, Jean-Charles</creatorcontrib><creatorcontrib>DIETRICH, Pierre-Yves</creatorcontrib><creatorcontrib>VALMORI, Danila</creatorcontrib><title>Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1</title><title>Journal of immunotherapy (1997)</title><addtitle>J Immunother</addtitle><description>Spontaneous immune responses to the cancer testis antigen NY-ESO-1 are frequently found in cancer patients bearing antigen-expressing tumors. In HLA-A2-expressing patients, naturally elicited NY-ESO-1-specific, tumor-reactive cytotoxic T lymphocytes (CTLs) are mostly directed against an immunodominant epitope corresponding to peptide NY-ESO-1 157-165. NY-ESO-1-specific CTLs can also be induced by synthetic peptide vaccines, but they are heterogeneous in terms of functional avidity and tumor reactivity. The authors investigated the structural bases of this phenomenon by analyzing the TCR features of natural and vaccine-induced NY-ESO-1-specific CTLs. The results indicate that CTLs from the two groups exhibit highly structurally conserved but distinct TCR features, suggesting that the synthetic peptides used for vaccination may fail to faithfully mimic the naturally processed antigen. Together, the results of this study underline the strength of TCR molecular monitoring and will be instrumental for the development and monitoring of vaccines aimed at eliciting CTLs with high tumor reactivity.</description><subject>Amino Acid Sequence</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cancer Vaccines - immunology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Medical sciences</subject><subject>Molecular Sequence Data</subject><subject>Neoplasm Proteins - immunology</subject><subject>Peptide Fragments - immunology</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Antigen, T-Cell - chemistry</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Vaccines, Subunit - immunology</subject><issn>1524-9557</issn><issn>1537-4513</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkV1vFCEUhonR2Fr9C4aY2BvDyscAM96Z7YcmjU3s9sIrwpyBSjPLjMA06Z_ob5ZtN9nDxTmB57wHeBH6xOiK0U5_pWwF92FFazDFRNeuRKPrJlev0DGTQpNGMvF6V_OGdFLqI_Qu53tKueINf4uOmGxFXfwYPZ2FXEKEgnNJC5Ql2RFv1r9xcrNLZQrJZRwijvb5aHzEE8CSUoh3-MGlvGT8YAFCdCTEYQE34PVZ-wVvCLhxrCp5nmKuGmXC5a_DZdlOieTZQfABsI0l3LmIf_0h5zfXhL1Hb7wds_uwzyfo9uJ8s_5Brq4vf66_XxGoTy1EDA1IzlvtuZAShG8b7pwQthm89KBZ4_tGMdX10A2DVJ5LLfsehAPF9NCJE3T6ojun6d_icjHbkHc3ttFNSzZKa6lbLSv47QWENOWcnDdzClubHg2jZueGocxUN8zBDfPshuGqNn_cT1n6rRsOrfvvr8DnPWAz2NEnGyHkA6e04JwK8R88OpWe</recordid><startdate>20050501</startdate><enddate>20050501</enddate><creator>LE GAL, Frédérique-Anne</creator><creator>AYYOUB, Maha</creator><creator>DUTOIT, Valérie</creator><creator>WIDMER, Valérie</creator><creator>JÄGER, Elke</creator><creator>CEROTTINI, Jean-Charles</creator><creator>DIETRICH, Pierre-Yves</creator><creator>VALMORI, Danila</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050501</creationdate><title>Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1</title><author>LE GAL, Frédérique-Anne ; AYYOUB, Maha ; DUTOIT, Valérie ; WIDMER, Valérie ; JÄGER, Elke ; CEROTTINI, Jean-Charles ; DIETRICH, Pierre-Yves ; VALMORI, Danila</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-3d4c52287f2355c3f842ee33a4df5fc714fb46169bc9dd56f2575bbc3ec617d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Amino Acid Sequence</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cancer Vaccines - immunology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Medical sciences</topic><topic>Molecular Sequence Data</topic><topic>Neoplasm Proteins - immunology</topic><topic>Peptide Fragments - immunology</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Antigen, T-Cell - chemistry</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Vaccines, Subunit - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LE GAL, Frédérique-Anne</creatorcontrib><creatorcontrib>AYYOUB, Maha</creatorcontrib><creatorcontrib>DUTOIT, Valérie</creatorcontrib><creatorcontrib>WIDMER, Valérie</creatorcontrib><creatorcontrib>JÄGER, Elke</creatorcontrib><creatorcontrib>CEROTTINI, Jean-Charles</creatorcontrib><creatorcontrib>DIETRICH, Pierre-Yves</creatorcontrib><creatorcontrib>VALMORI, Danila</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of immunotherapy (1997)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LE GAL, Frédérique-Anne</au><au>AYYOUB, Maha</au><au>DUTOIT, Valérie</au><au>WIDMER, Valérie</au><au>JÄGER, Elke</au><au>CEROTTINI, Jean-Charles</au><au>DIETRICH, Pierre-Yves</au><au>VALMORI, Danila</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1</atitle><jtitle>Journal of immunotherapy (1997)</jtitle><addtitle>J Immunother</addtitle><date>2005-05-01</date><risdate>2005</risdate><volume>28</volume><issue>3</issue><spage>252</spage><epage>257</epage><pages>252-257</pages><issn>1524-9557</issn><eissn>1537-4513</eissn><coden>JOIMF8</coden><abstract>Spontaneous immune responses to the cancer testis antigen NY-ESO-1 are frequently found in cancer patients bearing antigen-expressing tumors. In HLA-A2-expressing patients, naturally elicited NY-ESO-1-specific, tumor-reactive cytotoxic T lymphocytes (CTLs) are mostly directed against an immunodominant epitope corresponding to peptide NY-ESO-1 157-165. NY-ESO-1-specific CTLs can also be induced by synthetic peptide vaccines, but they are heterogeneous in terms of functional avidity and tumor reactivity. The authors investigated the structural bases of this phenomenon by analyzing the TCR features of natural and vaccine-induced NY-ESO-1-specific CTLs. The results indicate that CTLs from the two groups exhibit highly structurally conserved but distinct TCR features, suggesting that the synthetic peptides used for vaccination may fail to faithfully mimic the naturally processed antigen. Together, the results of this study underline the strength of TCR molecular monitoring and will be instrumental for the development and monitoring of vaccines aimed at eliciting CTLs with high tumor reactivity.</abstract><cop>Hagerstown, MD</cop><cop>Philadelphia,PA</cop><pub>Lippincott</pub><pmid>15838382</pmid><doi>10.1097/01.cji.0000161398.34701.26</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1524-9557 |
| ispartof | Journal of immunotherapy (1997), 2005-05, Vol.28 (3), p.252-257 |
| issn | 1524-9557 1537-4513 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67757875 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Amino Acid Sequence Antigens, Neoplasm - immunology Antineoplastic agents Biological and medical sciences Cancer Vaccines - immunology Humans Immunotherapy Medical sciences Molecular Sequence Data Neoplasm Proteins - immunology Peptide Fragments - immunology Pharmacology. Drug treatments Receptors, Antigen, T-Cell - chemistry T-Lymphocytes, Cytotoxic - immunology Vaccines, Subunit - immunology |
| title | Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A54%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distinct%20structural%20TCR%20repertoires%20in%20naturally%20occurring%20versus%20vaccine-induced%20CD8+%20T-cell%20responses%20to%20the%20tumor-specific%20antigen%20NY-ESO-1&rft.jtitle=Journal%20of%20immunotherapy%20(1997)&rft.au=LE%20GAL,%20Fr%C3%A9d%C3%A9rique-Anne&rft.date=2005-05-01&rft.volume=28&rft.issue=3&rft.spage=252&rft.epage=257&rft.pages=252-257&rft.issn=1524-9557&rft.eissn=1537-4513&rft.coden=JOIMF8&rft_id=info:doi/10.1097/01.cji.0000161398.34701.26&rft_dat=%3Cproquest_cross%3E67757875%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67757875&rft_id=info:pmid/15838382&rfr_iscdi=true |